Dyne Therapeutics

Edit info

Founded: 2017

Location: Waltham, MA

Employee range: 1 - 10

Clinical stage: Clin1/Clin2

Therapy area: Myotonic muscular dystrophy type 1

Drug types: MUS, GEN

Lead product: DYNE-101

Funding: $168M stock Jan 2021; $268M IPO Sep 2020; $115M Aug 2020; $50M Apr 2019

Investors: Vida Ventures, Surveyor Capital, Wellington Management Company, Logos Capital, Franklin Templeton, Atlas Venture, Forbion, MPM Capital

dyne-tx.com

linkedin.com

job board

Business:

Antibody-Oligonucleotide Treatments for Muscle Diseases

Drug notes:

DYNE-251 Clin1/Clin2 DMD; DYNE-301 Clin0 facioscapulohumeral muscular dystrophy; 4 undisclosed programs RD/Clin0 DMD

About:

Dyne Therapeutics is developing therapeutics for patients living with muscle diseases with the aim of stopping or reversing disease progression. Many muscular diseases have a genetic underpinning: Dyne is using their proprietary FORCETM platform to develop targeted, modern oligonucleotide therapeutics to address these genetic defects and slow disease progression. Dyne’s therapeutics consist of an antibody to target the drug to the muscle, a payload that consists of either antisense oligonucleotides or short interfering RNAs to target the genetic basis of the disease, and linker to combine the two units. Dyne’s lead product candidate, DYNE-101 is currently anticipated for clinical trials for patients with Myotonic Dystrophy.